key: cord-0779918-zvp76fe2
authors: Bishop, C. W.; Ashfaq, A.; Melnick, J. Z.; Vazquez-Escarpanter, E.; Fialkow, J. A.; Strugnell, S. A.; Choe, J.; Kalantar-Zadeh, K.; Federman, N. C.; Ng, D.; Adams, J. S.
title: Results From the REsCue Trial: A Randomized Controlled Trial with Extended-Release Calcifediol in Symptomatic Outpatients with COVID-19.
date: 2022-02-05
journal: nan
DOI: 10.1101/2022.01.31.22270036
sha: e0f4adc7b79223f2cf0c635f82267e9da388f211
doc_id: 779918
cord_uid: zvp76fe2

Importance: The benefit of vitamin D treatment for coronavirus disease 2019 (COVID-19) remains unclear. Objective: To investigate the effect of raising serum total 25-hydroxyvitamin D (25D) to 50-100 ng/mL with oral extended-release calcifediol (ERC) on time to symptom resolution in mild to moderate COVID-19. Design, Setting, and Participants: A multicenter, randomized, double-blind, placebo-controlled study evaluated treatment of 160 outpatients with COVID-19 diagnosed between November 2020 and October 2021. Interventions: Patients were treated for 4 weeks with ERC (30 mcg/capsule; 300 mcg on Days 1-3 and 60 mcg on Days 4-27) or placebo. Outcome Measures: Primary endpoints were raising serum 25D to >=50 ng/mL at Day 14 and resolution time for five aggregated symptoms. Secondary endpoints included resolution time for aggregated and individual symptoms as a function of serum 25D and changes in clinical biomarkers. Results: 171 subjects randomized, 160 treated and 134 (65 ERC and 69 placebo) retained. Average age was 43 (range: 18-71); 59% female, 92% White, 80% Hispanic, 7% African-American, 1% Other, 76% overweight, 40% obese, 26% comorbidities, mean baseline 25D of 37+-1 (SE) ng/mL. ERC increased mean 25D to 82+-ng/mL (p<0.001) by Day 7; 88% of subjects attained a level >=50 ng/mL; the placebo group trended lower. Resolution time for five aggregated symptoms was unchanged by ERC given that two composite non-respiratory symptoms responded poorly. Prespecified analyses showed that respiratory symptoms tended to resolve earlier when serum 25D levels reached >=50 ng/mL, but statistical significance was limited by small sample size and non-compliance: 25D increased in seven placebo subjects (unauthorized supplementation) and none occurred in five ERC subjects (failure to dose). A post-hoc composite of three respiratory symptoms (trouble breathing, chest congestion and dry or hacking cough) resolved 3.0 days faster when 25D was elevated at Days 7 and 14 (p<0.05); chest congestion resolved 4.0 days faster with 25D increases of >=25 ng/mL (p<0.05). Safety concerns including hypercalcemia were absent with ERC treatment. Conclusions and Relevance: ERC was effective in increasing serum 25D in outpatients with COVID-19, which may have accelerated resolution of respiratory symptoms suggesting mitigation of COVID-19 pneumonia risk, findings which warrant further study. Trial Registration: ClinicalTrials.gov identifier NCT04551911

symptoms responded poorly. Prespecified analyses showed that respiratory symptoms tended 1 to resolve earlier when serum 25D levels reached ≥50 ng/mL, but statistical significance was 2 limited by small sample size and non-compliance: 25D increased in seven placebo subjects 3 (unauthorized supplementation) and none occurred in five ERC subjects (failure to dose). A 4 post-hoc composite of three respiratory symptoms (trouble breathing, chest congestion and 5 dry or hacking cough) resolved 3.0 days faster when 25D was elevated at Days 7 and 14 6 (p<0.05); chest congestion resolved 4.0 days faster with 25D increases of ≥25 ng/mL (p<0.05). 7 Safety concerns including hypercalcemia were absent with ERC treatment. 8 Conclusions and Relevance: ERC was effective in increasing serum 25D in outpatients with 9 COVID-19, which may have accelerated resolution of respiratory symptoms suggesting 10 mitigation of COVID-19 pneumonia risk, findings which warrant further study. 1 Vitamin D repletion is purported to reduce the risk of infection with severe acute 2 respiratory syndrome coronavirus 2 (SARS-CoV-2) 1,2 , mitigate severity of coronavirus disease 3 2019 (COVID- 19) 3 and accelerate recovery 4 . Sufficient serum total 25-hydroxyvitamin D (25D) is 4 postulated to potentiate COVID-19 vaccine effectiveness 5 , boost innate and control adaptive 5 immunity 6, 7 , and reduce post-infection cytokine storm 6 and lung injury 8 . A serum 25D level of 6 approximately 50 ng/mL is proposed as the theoretical threshold for zero mortality from 7 COVID-19 based on regression analysis of decreasing deaths rates with rising serum 25D levels 9 . 8 The purported benefits of 25D repletion remain fully unsubstantiated in prospective 9 randomized controlled trials (RCTs). In one of only a few RCTs, administration of a single oral 10 dose of 200,000 IU of cholecalciferol (vitamin D3) to patients with moderate to severe COVID-19 11 failed to shorten hospital stays despite raising mean serum 25D from a baseline of 21.2 to 44.4 12 ng/mL, diminishing support for vitamin D repletion 10 . 13 The present RCT sought to explore the benefit of raising serum 25D to at least 50 ng/mL, 14 a level considered by some to be of concern 11 , on time to resolution of symptoms in COVID-19 15 outpatients. The working hypothesis was that controlled, progressive elevation of 25D to this 16 level with extended-release calcifediol (ERC) would safely boost the human innate immune 17 response to SARS-CoV-2 and accelerate recovery via intracrine production of calcitriol in 18 immune cells, such as macrophages, which co-express 25-hydroxyvitamin D-1α-hydroxylase 19 (CYP27B1) and vitamin D receptor (VDR) in response to viral infection 12 . Apt selection of 20 appropriate patient-reported outcomes as endpoints was hampered by the dearth of 21 information regarding which COVID-19 symptoms respond to vitamin D treatment, leading to 22 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 5, 2022. ; https://doi.org/10.1101/2022.01.31.22270036 doi: medRxiv preprint selection of a primary efficacy endpoint representing a "best guess" for finding a clinically 1 meaningful vitamin D signal. To compensate, this proof-of-concept study explored a broad 2 range of symptoms and used numerous prespecified and post-hoc analyses to characterize 3 potential signals. 4 

This multicenter trial (NCT04551911) titled "A Randomized, Double-Blind Placebo- 6 Controlled Study to Evaluate the Safety and Efficacy of Rayaldee (calcifediol) Extended-release 7 Capsules to Treat Symptomatic Patients Infected with SARS-CoV-2 (REsCue)" enrolled 8 symptomatic COVID-19 outpatients from 10 sites across the United States and randomized 9 them in a 1:1 ratio for 4 weeks of treatment with ERC (30 mcg/capsule) or placebo and a 2- 10 week follow-up. ERC was chosen as the test intervention because it has been previously shown 11 to safely and effectively raise serum 25D to targeted levels of 50-100 ng/mL and suppress 12 elevated intact parathyroid hormone (iPTH) when administered at 30 mcg/day and escalating, 13 as needed, to 60 mcg/day in patients with stage 3 or 4 chronic kidney disease (CKD). 13 Dosing 14 with ERC in the current study was designed to raise 25D more quickly, but in a controlled, 15 progressive manner, to this same target range well before Day 7, beginning with 300 mcg (10 16 capsules) on each of Days 1, 2 and 3 followed by 60 mcg (2 capsules) on Days 4 through 27. 17 Doses were administered at bedtime after fasting for three hours following dinner, and subjects 18 were instructed to remain fasting for 3 hours after dosing. Thirty-four COVID-19 symptoms 19 were self-reported daily using the FLU-PRO Plus © questionnaire, an outcome tool validated for 20 respiratory tract viral infections 14 . Symptoms were scored using multipoint scales ranging, most 21 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All patients provided written informed consent before participation in the study. 4 Patients were enrolled between November 2, 2020 and August 27, 2021 after testing positive 5 for SARS-CoV-2 infection within the previous three days via reverse transcription polymerase 6 chain reaction (RT-PCR) or another substitutable FDA-authorized test. They were ≥18 years of 7 age, and had mild to moderate COVID-19 (absence of clinical signs indicative of more severe 8 disease such as oxygen saturation <94% or respiration rate >30 bpm). They were required to 9 have symptoms during screening with mean scores of ≥1.5 for each of the chest/respiratory 10 and body/systemic domains of the FLU-PRO Plus © questionnaire. They were instructed to forgo 11 use of vitamin D supplements during the study. Patients were excluded if: they were pregnant 12 or breastfeeding; had recently taken systemic glucocorticoid medications; had a recent history 13 of primary hyperparathyroidism, kidney stones, hypercalciuria or hypercalcemia, cardiovascular 14 disease, poorly controlled hypertension, arrhythmias, chronic granuloma-forming disease or 15 chronic liver disease; history in the past five years of multiple myeloma or carcinoma of the 16 breast, lung or prostate; any surgical or medical condition that might significantly alter the 17 absorption, distribution, metabolism, or excretion of vitamin D; ongoing treatment with 18 thiazide diuretics; history of hyperphosphatemia, hyperuricemia or gout; estimated glomerular 19 filtration rate (eGFR) < 15 mL/min/1.73m²; or serum calcium ≥9.8 mg/dL within the last three 20 months. 21 22 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The study was approved by Advarra (Columbia, MD), a central Institutional Review 2 Board (IRB), and overseen by an independent five-member Data Safety Monitoring Board 3 (DSMB) comprised of an expert in viral disease pathogenesis, a nephrologist, a biostatistician, a 4 pulmonary medicine expert and an endocrinologist experienced in clinical safety monitoring. 5 The monitor reduced the maintenance dose to one capsule per day at Day 21 if serum total 25D 6 exceeded 100 ng/mL or serum total calcium (corrected for low albumin) exceeded 10.5 mg/dL. 7 Subjects, study personnel and the sponsor (and its designees, with the exception of the DSMB 8 and three unblinded members of the data management team) were blinded until after 9 database lock to treatment assignments and to serum vitamin D metabolite laboratory data. 10 Outcome Measures 11 One primary endpoint was attainment of the targeted serum total 25D level by Day 14. 12 A second was time to resolution of five composite COVID-19 symptoms (trouble breathing, 13 chest congestion, dry or hacking cough, body aches or pains, chills or shivering). These 14 symptoms were part of the chest/respiratory and body/systemic domains of the FLU-PRO Plus © 15 questionnaire for which mean scores of ≥1.5 were required for enrollment. The composite 16 respiratory symptoms (trouble breathing, chest congestion, dry or hacking cough) were 17 considered indicative of pulmonary compromise. The other two composite symptoms (body 18 aches or pains, chills or shivering) were considered indicative of systemic inflammatory 19 responses to viral infection. An aggregate score for the primary endpoint related to five COVID- 20 19 symptoms was selected in view of the observed heterogeneity in COVID-19 symptom 21 profiles; not all subjects experienced the same symptoms or degree of symptom severity. A 22 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 5, 2022. ; https://doi.org/10.1101/2022.01.31.22270036 doi: medRxiv preprint score of ≤5, or a mean of ≤1 for each composite symptom, was deemed appropriate because 1 the threshold of ≤1 described minor symptom severity (at worst "a little bit") which seemed 2 unlikely to presage a poor outcome. Resolution was defined as a reduction in the total baseline 3 score (maximum of 20) for the five symptoms to or below 5 for a minimum of three consecutive 4 days. Secondary endpoints included time to resolution of each composite symptom and of 5 aggregated symptoms as a function of serum 25D. 6 Safety endpoints included adverse events detected by physical examinations, vital signs, 7 electrocardiograms, hematology and clinical chemistries. Special attention was given to 8 changes in serum calcium and phosphorus, and eGFR, which presage potential hypercalcemia, 9 hyperphosphatemia and kidney damage. Exploratory endpoints included changes in serum 10 1,25-dihydroxyvitamin D (1,25D) and LL37 cathelicidin antimicrobial peptide, and plasma iPTH. 11 Laboratory Procedures 12 BioReference Laboratories (Elmwood Park, NJ) analyzed serum total 25D by LC-MS, 13 plasma iPTH by electrochemiluminescence (Roche Elecsys) and serum total 1,25D by 14 chemiluminescence (DiaSorin Liason). Syneos Health (Quebec, Canada) analyzed serum LL37 by 15 ELISA (LSBio). The circulating neutrophil:lymphocyte ratio was obtained from the complete 16 blood cell count as routinely performed. 17 Statistical Analysis 18 Results from analysis of the per-protocol (PP) population rather than the full analysis set 19 (FAS) are presented herein as the study merely sought to identify a clinically meaningful vitamin 20 D signal in the treatment of COVID-19 outpatients and guide the design of a larger, 21 confirmatory follow-on study.

22 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 5, 2022. ;

The two primary endpoints were tested hierarchically to maintain an overall one-sided 1 alpha level of 0.025. The first, attainment of serum 25D levels of ≥50 ng/mL, was assessed with 2 a Chi-square statistic. The second, number of days to resolution of five aggregated symptoms, 3 was analyzed with a Cox proportional hazards model with three covariates considered to have 4 possible influence on treatment efficacy: baseline FLU-PRO Plus © score for the five aggregated 5 symptoms, baseline serum 25D, and body weight. The log-rank test was used post-hoc to 6 compare Kaplan-Meier curves examining time to resolution of individual or aggregated 7 symptoms as a function of increase (versus lack thereof) in serum total 25D at both Days 7 and 8 14. Subjects who did not achieve symptom resolution prior to ending participation in the study 9 (3 to 19% depending on the symptom being evaluated; mean = 8.8%) were right censored after 10 the last day when data were obtained. Other efficacy endpoints were analyzed at each time 11 point using appropriate t-tests. 12 

A total of 241 patients provided written informed consent and were screened for 15 eligibility (Figure 1 ). Of these, 171 met all selection criteria and were randomized to one of the 16 two treatment groups. The most common reason for failing screening was insufficient severity 17 of COVID-19 symptoms. Five subjects withdrew consent prior to dosing, and six failed to receive 18 the shipment of study drug, leaving 160 subjects (80 per treatment group) who received at 19 least one dose of study drug (safety population). Eight subjects assigned to ERC and 5 subjects 20 assigned to placebo achieved symptom resolution prior to dosing and were excluded from 21 analysis, leaving 147 subjects (72 ERC and 75 placebo) in the FAS. Thirteen subjects had major 22 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 5, 2022. ; https://doi.org/10.1101/2022.01.31.22270036 doi: medRxiv preprint deviations from the protocol (e.g., less than 80% dosing compliance as documented in daily 1 diaries) prior to resolution of symptoms and were excluded from the PP population, which 2 consisted of 134 subjects (65 ERC and 69 placebo). 3 The average age of PP subjects was 43 (range: 18-71); 59% were female, 92% White, 7% 4 African-American, 1% Other, 76% were overweight and 40% obese based on body mass index 5 (BMI) greater than 25 and 30, respectively. Approximately 26% had comorbidities, most 6 commonly hypertension. Baseline mean serum total 25D was 37±1 (SE) ng/mL, with 95% or 7 72% of subjects having values of at least 20 or 30 ng/mL, respectively, two thresholds widely 8 viewed as lower limits of adequacy 11, 15 . Baseline characteristics of the PP population are shown 9 in Table 1 ; no significant differences were evident between treatment groups. 10 

Mean serum 25D levels increased with ERC treatment to 82±4 (SE) ng/mL (p<0.001) by 12 Day 7 and remained elevated for the duration of the study, with 88% of subjects attaining the 13 targeted level of ≥50 ng/mL (Figure 2A) . Attainment of this endpoint was unaffected by body 14 weight or BMI. In contrast, mean serum 25D trended lower with placebo treatment. Ten 15 subjects receiving ERC required dose reductions at Day 21 due to 25D levels rising above 100 16 ng/mL. ERC treatment produced similar mean increases in serum 25D in each baseline 25D 17 category (Figure 2B ). 18 The time to resolution for the five aggregated COVID-19 symptoms was statistically 19 unchanged by ERC given that two composite non-respiratory symptoms responded poorly 20 ( Figure 3A) . Prespecified analyses showed that the other three respiratory symptoms tended to 21 resolve sooner, for example, chest congestion (Figure 3B) , when serum 25D levels reached at 22 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 5, 2022. least 50 ng/mL; however, significance of the changes was limited by small sample size and 1 dosing non-adherence: 25D increases occurred in seven placebo subjects (unauthorized 2 supplementation) and none occurred in five ERC subjects (failure to dose). These three 3 respiratory symptoms (trouble breathing, chest congestion and dry or hacking cough), when 4 analyzed together post-hoc, resolved 3.0 days faster (Figure 3C ) on average when serum 25D 5 was elevated above baseline at Days 7 and 14 (p<0.05); chest congestion resolved 3.4 ( Figure   6 3D) days faster (p<0.05). Resolution time for chest congestion was accelerated by 4.0 days with 7 25D increases of at least 25 ng/mL (p<0.05). 8 The sample size of the study was too small to evaluate the effect of treatment on 9 incidence of urgent care visits, oxygen saturation below 94% and hospitalizations. Changes in 10 laboratory measurements during treatment are summarized in Table 2 . Serum total 1,25D, 11 serum LL37 and the neutrophil:lymphocyte ratio all trended upward with ERC treatment and 12 downward with placebo, while serum calcium and phosphorus, plasma iPTH and eGFR 13 remained stable. Mean serum calcium in the ERC group was unaffected by baseline or post-14 treatment serum 25D level. Episodes of hypercalcemia or hyperphosphatemia were not 15 observed, even in subjects whose serum 25D exceeded 100 ng/mL. Other safety endpoints 16 showed no clinically meaningful changes with treatment. 17 

This randomized, double-blind, placebo-controlled clinical trial showed that ERC 19 treatment was effective in increasing serum total 25D to levels of at least 50 ng/mL, which may 20 have yielded significantly shorter resolution times for three aggregated respiratory symptoms 21 (trouble breathing, chest congestion and dry or hacking cough) commonly observed in patients 22 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 5, 2022. ; https://doi.org/10.1101/2022.01.31.22270036 doi: medRxiv preprint with mild to moderate COVID-19. Of these symptoms, chest congestion showed the greatest 1 response, resolving 3.4 to 4.0 days earlier, depending on the degree to which 25D was elevated. 2 These findings suggest that raising serum 25D with ERC may mitigate, without adverse effects, 3 the risk of COVID-19 pneumonia. 4 A possible mechanism 12 underlying these findings is induction of endogenous human 5 antimicrobial peptides, such as LL37, that can boost the host's immune response to the virus. 6 Serum LL37, which trended upwards in this study, is the product of the cathelicidin 7 antimicrobial peptide (CAMP) gene and is secreted from monocyte/macrophages, dendritic 8 cells and neutrophils in response to viral or bacterial infection. The innate immune response is 9 initiated and perpetuated in antigen-presenting cells by pathogen-associated molecular 10 patterns derived from the viral capsid and other unique signatures of the infecting virus 11 interacting with pattern recognition receptors (e.g., Toll-like receptors [TLR]). TLR activation 12 leads to up-regulation of expression of the intracellular CYP27B1 and VDR; the former event up- 13 regulates the enzymatic conversion of the prohormone calcifediol to its active metabolite, 14 calcitriol, which can then engage the VDR in an intracrine mode and control CAMP gene 15 expression. Only in higher primates, including man, is the CAMP gene regulated by calcitriol 17 . 16 Serum 25D of approximately 50 ng/mL or more is thought sufficient to support 17 intracellular generation of 1,25D, activation of the VDR, transactivation of the CAMP gene and 18 production and release of LL37 to combat SARS-CoV-2 proliferation in the host 16 . Serum levels 19 of 1,25D and LL37 were observed to trend upward with ERC treatment, reflecting their elevated 20 intracellular concentrations in the inflammatory microenvironment of the lung. The circulating 21 neutrophil:lymphocyte ratio, a purported biomarker of disease activity in COVID-19 18 , went up 22 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 5, 2022. ; https://doi.org/10.1101/2022.01.31.22270036 doi: medRxiv preprint in this study, but declined significantly with immediate-release calcifediol (IRC) in a previously 1 reported RCT 19 conducted in patients hospitalized with more severe COVID-19. Aside from this 2 biomarker, no other significant differences between IRC and placebo treatment were reported 3 in that earlier RCT. Possible explanations for these divergent findings include fewer participants 4 (28 active, 34 placebo), more severe COVID-19, more rapid and proximal release of calcifediol, 5 and lower achieved mean (SD) serum 25D level (42.0±13.7 ng/mL). Release of calcifediol from 6 ERC is gradual, continues over a period of 12 hours (based on in vitro dissolution), and likely 7 occurs primarily in the colon. 8 The current study differed from previous evaluations of vitamin D supplementation in 9 COVID-19 patients in two ways. First, it targeted achievement of a high serum 25D exposure 10 (50-100 ng/mL) with downward dose adjustment, as needed. This approach was chosen in view 11 of the reported inverse relationship between baseline 25D and observed increase with vitamin 12 D supplementation 20 (a relationship that was not observed in this study), and the known 13 adverse impact of adipose tissue on 25D bioavailability that can be readily overcome with ERC, 14 but not with vitamin D supplements 21 . Prescription and non-prescription supplements of 15 cholecalciferol (vitamin D3) and ergocalciferol (vitamin D2) are fat-soluble, poorly absorbed in 16 the intestine, accumulate preferentially in adipose tissue 22, 23 , possess low affinities for the 17 serum vitamin D binding protein (DBP) 22 and are poorly mobilized from adipose into circulation 18 for hepatic activation 24 . Such supplements have multi-day delays in raising serum 25D 25 , and 19 prove to be unreliable in raising serum 25D in overweight or obese patients who are at high risk 20 for COVID-19 15, 26 . Further, hepatic 25-hydroxylase activity is reduced in obesity, also blunting 21 the intended elevation of serum 25D 27 . In contrast, calcifediol requires no hepatic activation 28 , 22 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The strengths of this study are the randomized, double-blind, placebo-controlled design; 8 targeting, safely achieving and maintaining uncommonly high and sustained serum 25D levels 9 of ≥50 ng/mL; examination of a broad spectrum of symptoms commonly associated with 10 COVID-19; and in-depth monitoring of patient outcomes and safety via weekly in-person clinic 11 visits. 12 

The inability of this study to show more significant differences in time to resolution for 14 respiratory symptoms is likely due to inadequate power (small sample size); the modest 15 severity of COVID-19 in the enrolled subjects; the fact that 17% of subjects assigned to placebo 16 treatment had, unexpectedly, serum 25D levels above 50 ng/mL at baseline; dosing 17 noncompliance (four previous but unpublished pharmacokinetic studies of a single 900 mcg ERC 18 loading dose in healthy volunteers have shown that no subject failed to achieve an increase in 19 serum 25D of at least 6 ng/mL); and, varying periods of time between onset of symptoms and 20 diagnosis in of COVID-19 as well as between diagnosis and initiation of ERC treatment. The 21 observed positive effect of 25D elevation on resolution of COVID-19 respiratory symptoms is 22 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 5, 2022. ; https://doi.org/10.1101/2022.01.31.22270036 doi: medRxiv preprint based on a post-hoc analysis and needs to be confirmed in a larger study with an appropriate 1 prespecified endpoint. 2 

ERC was effective in increasing serum total 25D to levels of at least 50 ng/mL in 4 outpatients with COVID-19 that may have accelerated resolution of respiratory symptoms, 5 suggesting mitigation of COVID-19 pneumonia risk. The positive findings from this RCT warrant 6 confirmation in additional larger studies. 7 8 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. are currently available from the study and take responsibility for the integrity of the data and 3 the accuracy of the data analysis. 4 Concept and design: Drs. Bishop, Ashfaq, Melnick, Federman and Adams. 5 Acquisition, analysis and interpretation: All authors. 6 Drafting of the manuscript: All authors. 7 Critical revision of the manuscript for important intellectual content: All authors. are paid OPKO clinical investigators; no other relationships or activities that could appear to 16 have influenced the submitted work. 17 Funding Support: The study was funded by OPKO. 18 Data Sharing Statement: All top-line data produced in the present study are summarized in the 19 manuscript. Additional analyses are ongoing as further laboratory data become available. 20 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Hydroxyvitamin D Levels (Per-protocol Population). Increase group: symptoms resolved in 66 subjects but not in 4 who were right-censored. No increase group: symptoms resolved in 49 subjects but not in 5 who were right-censored. The difference between the plotted curves is statistically significant (P<0.05). A total of 10 subjects did not have a total score of >3 at treatment in at treatment initiation (Day 1) and were excluded from analysis. subjects but not in 4 who were right-censored. The difference between the plotted curves is statistically significant (P<0.05). A total of 19 subjects did not have chest congestion at treatment initiation (Day 1) and were excluded from analysis.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 5, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 5, 2022. ; https://doi.org/10.1101/2022.01.31.22270036 doi: medRxiv preprint

SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels

Evidence that vitamin D supplementation could reduce risk of Influenza and COVID-19 infections and deaths

Vitamin D deficiency is associated with higher hospitalization risk from COVID-19: a retrospective case-control study

Association of vitamin D deficiency with COVID-19 infection severity: systematic review and meta-analysis

Putative role of vitamin D for COVID-19 vaccination

Mechanisms in endocrinology:vitamin D and COVID-19

Vitamin D's effect on immune function

Vitamin D and COVID-19: an overview of recent evidence

COVID-19 mortality risk correlates inversely with vitamin D3 status, and a mortality rate close to zero could theoretically be achieved at 50 ng/mL 25(OH)D3: results of a systematic review and meta-analysis

Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial

Dietary reference intakes for calcium and vitamin D

Emerging roles of vitamin D-induced antimicrobial peptides in antiviral innate immunity

Use of extended-release calcifediol to treat secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease

Development of the Flu-PRO: a patient-reported outcome (PRO) instrument to evaluate symptoms of influenza

Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline

Vitamin D's role in reducing risk of SARS-CoV-2 and COVID-19 incidence, severity, and death

Exaptation of an ancient Alu short interspersed element provides a highly conserved vitamin D-mediated innate immune response in humans and primates

Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China

Treatment with 25-hydroxyvitamin D3 (calcifediol) is associated with a reduction in the blood neutrophil-to-lymphocyte ratio marker of disease severity in hospitalized patients with COVID-19: a pilot multicenter, randomized, placebo-controlled, double-blinded clinical trial

The serum 25-hydroxyvitamin D response to vitamin D supplementation is related to genetic factors, BMI, and baseline levels

Obesity: a key consideration in the management of secondary hyperparathyroidism

Mobilizing vitamin D from adipose tissue: the potential impact of exercise

25-Hyderoxycholecalciferol response to single oral cholecalciferol loading in the normal weight, overweight and obese

Reduced hepatic synthesis of calcidiol in uremia

Vitamin D2 is much less effective than vitamin D3 in humans

The importance of body weight for the dose response relationship of oral vitamin D supplementation and serum 25-hydroxyvitamin D in healthy volunteers

Obesity decreases hepatic 25-hydroxylase activity causing low serum 25-hydroxyvitamin D

Extended-Release calcifediol in renal disease

Intestinal absorption of cholecalciferol and 25-hydroxycholecalciferol in chronic cholestatic liver disease

Profile of ligand specificity of the vitamin D binding protein for 1-alpha,25-dihydroxyvitamin D3 and its analogs

Vitamin D3 increase in abdominal subcutaneous fat tissue after supplementation with vitamin D3